P&G (PG) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Q1 2025 results were unimpressive but aligned with expectations; Muscle Pharm's turnaround remains elusive despite management efforts. Management is actively seeking M&A opportunities, targeting niche brands due to heavy competition from larger players and private equity. Q2 is expected to show growth, driven by market resilience, easier comps, and early signs of revenue and EBITDA improvement.

In yet another milestone for the ETF space, American Century Investments saw its suite surpass $75 billion in total AUM. The firm, which also offers ETFs under the Avantis Investors brand, offers ETFs like its largest, the Avantis U.S. Small Cap Value ETF (AVUV).

Q2 Metals Corp (TSX-V:QTWO) is preparing its first exploration target for the Cisco lithium project in Quebec. The Vancouver, BC-based company is estimating there could be between 215 and 329 million tonnes of rock containing 1% to 1.38% lithium oxide (Li₂O) at the target.

RTX Q2 earnings and sales beat estimates on broad segment growth. However, the company trims its 2025 EPS forecast.

The average of price targets set by Wall Street analysts indicates a potential upside of 34.4% in Insight Enterprises (NSIT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

AXT Inc (AXTI) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, AXTI's 50-day simple moving average crossed above its 200-day simple moving average, known as a "golden cross.

The consensus price target hints at a 32.6% upside potential for Cars.com (CARS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

The mean of analysts' price targets for Genmab (GMAB) points to a 40% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

The consensus price target hints at a 28.6% upside potential for Oneok (OKE). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

IBM (NYSE:IBM) is set to publish its earnings report on Wednesday, July 23, 2025. Over the past five years, IBM has shown a pattern of achieving positive one-day returns in 63% of the cases following its earnings releases.

The rail unit of Warren Buffett's firm reportedly hired Goldman as a financial advisor after Union Pacific considers a deal for Norfolk Southern.

Shares of Kohl's surged on Tuesday, leading to a temporary halt in trading due to volatility. The legacy department store's stock more than doubled in early trading, but those gains were soon wiped out.

PARAMUS, N.J., July 22, 2025 (GLOBE NEWSWIRE) -- Alexander's, Inc. (NYSE: ALX) today announced that it will file its quarterly report on Form 10-Q for the quarter ended June 30, 2025 with the U.S. Securities and Exchange Commission and issue its second quarter earnings release on Monday, August 4, 2025, before the New York Stock Exchange opens.

NEW YORK, July 22, 2025 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a securities class action lawsuit has been filed in the United States District Court for the Northern District of California on behalf of all persons or entities who purchased or otherwise acquired Alto Neuroscience, Inc. (“Alto Neuroscience” or the “Company”) (NYSE: ANRO) (i) between February 2, 2024 and October 22, 2024, inclusive (the “Class Period”); and/or (ii) pursuant and/or traceable to Alto Neuroscience's registration statement issued in connection with Alto Neuroscience's February 2, 2024 initial public offering (“IPO”).

SAN DIEGO, July 22, 2025 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Hims & Hers Health, Inc. (NYSE: HIMS) securities between April 29, 2025 and June 23, 2025, inclusive (the “Class Period”), have until Monday, August 25, 2025 to seek appointment as lead plaintiff of the Hims & Hers class action lawsuit. Captioned Sookdeo v. Hims & Hers Health, Inc., No. 25-cv-05315 (N.D. Cal.), the Hims & Hers class action lawsuit charges Hims & Hers as well as certain of Hims & Hers' top executives with violations of the Securities Exchange Act …

Steel Dynamics misses second-quarter earnings and revenue estimates as trade tensions and inventory overhang weigh on shipments.

Find out why Zacks has assigned Stratus a "Neutral" rating, being the first on Wall Street to initiate coverage on the stock. Explore how strategic land holdings and savvy asset sales are balanced by revenue volatility and debt exposure.

IBM's Q2 results may get a lift from surging Software revenues, driven by watsonx.ai, acquisitions and new AI labs.

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.